(AHCO) Adapthealth - Ratings and Ratios

AdaptHealth Corp (NASDAQ:AHCO) is a leading distributor of home medical equipment (HME), medical supplies, and related services across the United States. The company specializes in providing essential medical products and services to patients with chronic conditions. Its offerings include sleep therapy equipment, such as CPAP and Bi-PAP devices, for individuals with obstructive sleep apnea. Additionally, AdaptHealth supplies medical devices and supplies for diabetes management, including continuous glucose monitors and insulin pumps. The company also provides HME to patients discharged from acute care facilities, oxygen therapy services, and other equipment for wound care, urological, incontinence, ostomy, and nutritional needs. Its product range extends to wheelchairs, hospital beds, oxygen concentrators, diabetes management supplies, orthopedic bracing, breast pumps, walkers, commodes, canes, and nutritional and incontinence supplies. AdaptHealth serves beneficiaries of Medicare, Medicaid, and commercial insurance payors. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, the company has expanded its reach through strategic acquisitions and partnerships, focusing on patient-centric services to enhance customer retention and market share.

Based on the provided data, AdaptHealth Corps stock is currently trading at $8.78, below its 50-day and 200-day moving averages of $9.55 and $10.11, respectively. This indicates a potential downtrend in the short to medium term. The average trading volume over the past 20 days is approximately 1.64 million shares, with an average true range (ATR) of 0.52, suggesting moderate volatility. From a fundamental perspective, the company has a market capitalization of $1.004 billion, with a price-to-earnings (P/E) ratio of 12.20 and a forward P/E of 6.77, indicating expectations of earnings growth. The price-to-book (P/B) ratio of 0.64 and price-to-sales (P/S) ratio of 0.31 suggest undervaluation relative to its assets and revenue. However, the return on equity (RoE) of 5.73% is relatively low, which may warrant closer examination. Overall, while the stocks technical indicators point to near-term weakness, the fundamental metrics suggest potential for long-term growth, particularly if the company can improve profitability and leverage its market position in the HME sector.